摘要
目的探讨血管紧张素转换酶抑制剂贝纳普利对糖尿病肾脏病变的保护作用和对细胞间粘附分子(ICAM-1)mRNA及蛋白表达的影响.方法STZ诱发大鼠糖尿病,实验设正常组,糖尿病对照组,贝纳普利组和胰岛素治疗组,贝纳普利1.1mg·kg-1·d-1治疗2月,观察肾脏肥大、尿蛋白变化以及用免疫组化和RT-PCR方法检测ICAM-1在肾组织的定位、半定量表达.结果与糖尿病组相比,贝纳普利能显著降低肾重/体重,24h尿微量白蛋白(P<0.01).免疫组化和RT-PCR半定量结果显示贝纳普利能显著降低ICAM-1表达(P<0.01).结论贝纳普利能够降低STZ诱发糖尿病大鼠肾脏组织ICAM-1 mRNA和蛋白表达,对糖尿病肾脏病变有保护作用.
OBJECTIVE To investigate the effect of Benazepril,an angiotensin-- converting enzyme inhibitor(ACEI),on the protection against diabetic nephropathy and on the of intercellular adhesion molecule--1 (ICAM--1) mRNA expression in diabetic at glomeruli. METHODS The rat model of diabetes mellitus (DM) was produced by injection of streptozoein(STZ) . After the treatment with Benazepril (1. 1mg·kg^-1·d^-1 for two months, glomerular hypertrophy and 24h urinary protein were measured,the expression of ICAM--1 was investigated by immunohistochemistry and RT--PCR. RESULTS Kidney weight/body weight index (KW/BW), urine protein during 24h increased significantly ( P 〈0.01) in DM model group compared with control. Meanwhile,Benazepril treatment could reduce KW/BW and urine protein during 24 hours. By immunohisto- chemistry and RT--PCR we observed that Benazepril can significantly inhibit the expression of ICAM- 1 (P 〈0. 01) . CONCLUSION Benazepril can suppress the overexpression of ICAM- 1,thus prevent the progression of diabetic nephropathy.
出处
《齐鲁药事》
2010年第2期114-117,共4页
qilu pharmaceutical affairs
关键词
血管紧张素转换酶抑制剂
糖尿病肾病
细胞间粘附分子
贝纳普利
Angiotensin-converting enzyme inhibitor
diabetie nephropathy
intercellular adhesion molecule--1
benazepril